Losartan to Improve Outcomes After Multi-ligament Knee Injury

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Multi-ligament Knee Injury
Interventions
DRUG

losartan 25 mg

Losartan is an angiotensin-II inhibitor that modulates the renin-angiotensin system by blocking the activation of angiotensin type 1 receptors, thus preventing binding with angiotensin-II and decreasing blood pressure. Losartan has a broader therapeutic potential for muscle healing and treatment for diseases ranging from rheumatoid arthritis, osteoarthritis, chronic kidney disease, Marfan syndrome, and fatty liver. TGF-β plays an active role in fibrosis leading to the formation of adhesions and scar tissue. By limiting the formation of adhesions and scar tissue, losartan may reduce pain, myofibroblast activity, synovitis, fibrosis, and cartilage degeneration.

OTHER

Placebo capsule

The placebo capsule will look identical to the active study drug, but will not have any active ingredient and will be filled with corn starch

Trial Locations (1)

02035

Mass General Brigham, Foxborough

All Listed Sponsors
collaborator

University of Kentucky

OTHER

collaborator

Walter Reed National Military Medical Center

FED

lead

Brigham and Women's Hospital

OTHER